PharmaPoint Report: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/3h6cg9/pharmapoint)
has announced the addition of the “PharmaPoint:
Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024”

report to their offering.

Although the past decade has seen the atopic dermatitis market remain
relatively unchanged and a saturated, highly genericized arena, the
coming decade could see the launch of the first biologic, which will set
a precedent and pave the way for others to follow suit.

By the mid-to-late term of our 2014 to 2024 forecast, Sanofi/Regeneron’s
dupilumab is expected to reshape the adult moderate and severe treatment
landscape and to slowly enter the market for younger patients with
milder forms of the disease.

Other events that are expected to invoke change to the previously
stagnant atopic dermatitis market include the launch of a non-steroidal
topical from Anacor, AN2728, generic erosion of branded topicals
Protopic and Elidel in the US.

Exciting times lay ahead for the atopic dermatitis marketplace, as the
above events are due to occur against the backdrop of increasing
research into the multiple etiologies that give rise to the disease.
With existing unmet need for a better treatment armamentarium for
severe, recalcitrant patients and an estimated drug-treated population
that hovers around the 110 million mark over the next decade, atopic
dermatitis represents an attractive dermatology sector for drug
developers, and this should fuel commercial interest into this
marketplace.

Key Questions Answered

– How will the atopic dermatitis market (sales and patient numbers)
evolve over the 10-year forecast period from 2014 to 2024?

– Which brands and specific drug classes did physicians select for their
atopic dermatitis patients in 2014 and how do they foresee their
prescribing behavior evolving over the next five years?

– How will the launch of late-stage pipeline therapies such as dupilumab
and AN2728 shape the future treatment landscape?

– What are the remaining unmet needs and opportunities for drug
developers within the atopic dermatitis market?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Opportunity and Unmet Need

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

  • Astellas
  • Meda
  • Sanofi/Regeneron/Boehringer Ingelheim
  • Anacor

For more information visit http://www.researchandmarkets.com/research/3h6cg9/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune
Disorders